Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. [electronic resource]
Producer: 20121218Description: 2826-35 p. digitalISSN:- 1528-0020
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- genetics
- Chromosomes, Human, Pair 21 -- genetics
- Chromosomes, Human, Pair 8 -- genetics
- Core Binding Factor Alpha 2 Subunit -- genetics
- Female
- Humans
- Leukemia, Myeloid, Acute -- drug therapy
- Male
- Middle Aged
- Neoplasm Recurrence, Local -- diagnosis
- Neoplasm Staging
- Neoplasm, Residual -- diagnosis
- Oncogene Proteins, Fusion -- genetics
- Prognosis
- Prospective Studies
- RNA, Messenger -- genetics
- RUNX1 Translocation Partner 1 Protein
- Real-Time Polymerase Chain Reaction
- Reverse Transcriptase Polymerase Chain Reaction
- Risk Assessment
- Survival Rate
- Translocation, Genetic -- genetics
- Young Adult
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.